Financial Results
Samsrita Labs Publishes Unaudited Results Notice
Samsrita Labs published newspaper notices regarding its unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
6
Neutral
6
Bullish
2
Bearish
12
Neutral
6
Bullish
28
Bearish
6
Neutral
0
Bullish
26
Bearish
6
Neutral
0
Bullish
26
Bearish
6
Neutral
0
Bullish
26
Bearish
6
Neutral
0
Bullish
26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Financial Results
Samsrita Labs published newspaper notices regarding its unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026.
Regulatory/Compliance Filing
Samsrita Labs reported no deviation or variation in the use of ₹339.10 lakh raised through its preferential issue for the quarter ended 30 September 2026.
Financial Results
Samsrita Labs approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with limited review reports.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Samsrita Labs Ltd (SAMSRITA) is currently trading at 12.06 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Samsrita Labs Limited is a diversified healthcare and bio-pharma company focused on stem cell research, new drug discovery, molecular diagnostics, CRO services and related hospital operations, pursuing manufacturing, trading and R&D of APIs, specialty drugs and nutraceuticals through collaborations, joint ventures and associate relationships since its origin as Dr Habeebullah Life Sciences Limited. The unaudited standalone and consolidated results for quarter and nine months ended 31 December 2025 show continuing operating losses with negative basic and diluted EPS, and the consolidated position is influenced by associate volatility and operational expenses, indicating limited near-term profitability despite ongoing R&D and collaborative activity. During the quarter Samsrita Labs Limited recorded a significant write-off of intangible assets under development amounting to approximately Rs 3.25 crore due to technological obsolescence; auditors issued an unmodified review report but emphasized the write-off, which materially reduced interim profitability and signals impairment of capitalized R&D or patent assets. The Board broadened corporate objects in April 2025 to include biofuels, food processing, green technologies and deep information technology, signaling planned strategic diversification beyond core bio-pharma; associate companies like Krisani Bio Sciences and Qrops Advisory materially contribute to consolidated results, reflecting a hybrid operating and investment approach.
Over the past 52 weeks, Samsrita Labs Ltd has traded between a low of ₹10.15 and a high of ₹24.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Samsrita Labs Ltd has a market capitalization of approximately 27.44. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Samsrita Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -7.02 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 27.44 Cr, Samsrita Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Samsrita Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Samsrita Labs Ltd is -7.02. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Samsrita Labs held its 30th AGM on August 10, 2026, via video conferencing, with 70 members attending.
Healthcare Services
Healthcare Service Provider
27 Cr
Low Risk
-7.0
59.7
—
2.4
24.55
10.15
Sales CAGR
Profit CAGR
ROE
ROCE
